Scarica l'app Stockscreener
40.94
2.99%
1.19
Precedente Chiudi:
$39.75
Aprire:
$39.67
Volume 24 ore:
1.62M
Relative Volume:
1.36
Capitalizzazione di mercato:
$7.41B
Reddito:
$455.99M
Utile/perdita netta:
$-285.01M
Rapporto P/E:
-12.56
EPS:
-3.26
Flusso di cassa netto:
$-164.61M
1 W Prestazione:
+7.20%
1M Prestazione:
-9.09%
6M Prestazione:
-3.90%
1 anno Prestazione:
-31.89%
Intervallo 1D:
$38.68
$41.09
Intervallo di 1 settimana:
$36.92
$41.09
Portata 52W:
$36.92
$70.13
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Nome
Legend Biotech Corp Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta LEGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| LEGN | 40.94 | 7.41B | 455.99M | -285.01M | -164.61M | -3.26 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-19 | Iniziato | Scotiabank | Sector Perform |
| 2023-11-06 | Iniziato | Goldman | Buy |
| 2023-05-25 | Iniziato | William Blair | Mkt Perform |
| 2023-05-22 | Iniziato | Daiwa Securities | Buy |
| 2023-03-29 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-11-02 | Iniziato | Evercore ISI | Outperform |
| 2022-11-01 | Iniziato | Cowen | Outperform |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-03-15 | Iniziato | Barclays | Overweight |
| 2022-01-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2020-07-01 | Iniziato | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Legend Biotech Corp Adr Borsa (LEGN) Ultime notizie
Legend Biotech Corp ADR (NASDAQ: LEGN) Has Great Upside Potential - Stocks Register
Thinking Of Investing In Bilibili Inc ADR (NASDAQ: BILI) Stock? Read This First - Stocks Register
Are Medtronic Plc (NYSE: MDT) Analysts Predicting A Spike? - Stocks Register
Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com
Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa
Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com
Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Legend Biotech appoints new President for CARVYKTI - Investing.com
Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance
Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register
Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India
Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India
Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily
Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily
Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily
BMO maintains steady target on Legend Biotech on strong sales - Investing.com
BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa
Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex
Legend Biotech Corp ADR’s results are impressive - US Post News
UnitedHealth, NVIDIA lead Tuesday's afternoon market cap stock movers By Investing.com - Investing.com UK
Legend Biotech maintains shares price target on steady Q3 growth - Investing.com
Legend Biotech Corp ADR’s Mixed Bag: Down -8.63% in 6 Months, Down 1.03% in 30 Days - The InvestChronicle
Market Insights: Legend Biotech Corp ADR (LEGN)’s Notable Gain of 1.62, Closing at 48.84 - The Dwinnex
Legend Biotech shares hold strong with positive outlook on robust Carvykti sales - Investing.com
Legend Biotech Corp ADR (LEGN) is a good investment, but the stock may be overvalued - US Post News
Redburn sees growth potential for Legend Biotech stock on Carvykti demand - Investing.com
Does Legend Biotech Corp ADR (LEGN) offer a good opportunity for investors? - SETE News
Legend Biotech stock maintains positive outlook with new Philadelphia R&D facility - Investing.com
Upward Trajectory: Legend Biotech Corp ADR (LEGN) Posts a Gaine, Closing at 48.68 - The Dwinnex
Legend Biotech Corp ADR (LEGN) stock analysis: A simple moving average approach - US Post News
You might want to take a look at Legend Biotech Corp ADR (LEGN) now - SETE News
Legend Biotech shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
BMO maintains Outperform rating on Legend Biotech shares on Carvykti data - Investing.com India
Legend Biotech shares maintain Buy rating from H.C. Wainwright - Investing.com India
Legend Biotech's SWOT analysis: carvykti success drives stock potential - Investing.com
Legend Biotech reiterates stock target, overweight on Phase III data - Investing.com
Legend Biotech stock poised for growth with compelling data on Carvykti - Investing.com
Legend Biotech Corp ADR (LEGN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Can you now get a good deal on Legend Biotech Corp ADR’s shares? - US Post News
There is no doubt that Legend Biotech Corp ADR (LEGN) ticks all the boxes. - SETE News
Closing Bell Recap: Legend Biotech Corp ADR (LEGN) Ends at 45.92, Reflecting a -5.38 Downturn - The Dwinnex
Analytical Lens: Exploring Legend Biotech Corp ADR (LEGN)’s Financial Story Through Ratios - The Dwinnex
Legend Biotech Corp Adr Azioni (LEGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):